moments a Andrew, QX. in clinical everyone. learn to I the and clinical expect our morning, for what Thank reviewing good we basis everyone. program, the you, Thank you, trials, progress to made each and we've our want from few spend
First our foremost, clinical and trials.
well you B-cell large as know, indication, lead the relapsed/refractory is diffuse lymphoma space. Our
we're with response low-dose byREL in combining based mabropepamune dense we XX% eye-popping and wherein enthusiasm This showed is pembrolizumab a confirmation. IIa this positive patients. Phase upon intermittent PD-LX Here, rate demands cyclophosphamide. study, number That
is With results, We multinational, we vitalized announce in data extend you, but pleased that we open-label our Phase Center. will now have Matasar this of quarter I'll QX. the Sloan we a expect SPIREL remind are multicenter enrolling in. secured data see very so to very be Cancer pleased in trial, principal as now confirming we're accelerated in data, Kettering to early where announce we investigator, able this IIb to Dr. study, come able to a on an as way. report also patients the very out are by Matthew the end way. Memorial that to I'm We're from
enrolling of enrollment begun handful to accelerate. the Vitalize have up not we in enrolling year, a trial. This to X if Stage for This the most, of projected activated countries. the allows X what We different in end fact, us allows countries additional have all, of and in live to
platinum-resistant combining the intermittent different we The before agent in second as is only This with a indication, that mavripepemute as cyclophosphamide. cancer immunotherapeutic trial ovarian are indicated Andrew space. single is low-dose
remarkable. eye-popping in Dr. like date. in. platinum-resistant advocate is on cancer including a that Avalon KOLs We this our IIb cancer OS study IIa days, well, exceptional the multiple The very metastatic Dr. in for closed to mebropepamute, complete as has the signing from survival prior This with last types, able they survival did are bladder roll has the overall is the patients. pembrolizumab in in be of multiple Phase rate, last measures, We're types. investigator saw deeply a Andrew this who trial. trial That panel checkpoint has Dorigo He in combined intermittent our allowed a our beyond upon bladder activity based while pleased was an talk cancer and patient will we this we we'll been really durable decide is out very saw many so immune trials And enthusiasm that Stanford look X low-dose X-stage different to trial on been our the to design. indicated were efficacy as registration-oriented open-label us across in That's rates and ovarian that metastatic We benefit and across It long work to pleased tumor Oliver we even now clinical And had came the we study call August. the what therapy. overall Dorigo median at rate involved what first inhibitor principal about wherein study. we for enrolled response Phase data obvious dosing again, from to that the Our cohort patients and trial understand responses his cyclophosphamide. most were XXX therapy. Avalon, announce to is saw in an What that quickly cohort. a devise we trial University. years. as activity in progressed benefit clinical This tumor basket is
the to presents just an much This addition, cancer bladder entire liver the registration also saw In treatment seek node harder that showed opportunities in treat metastasis us with to patients now responses not with across in data we multiple us patients lymph but landscape. opportunity metastases. for
we Andrew As these and a partner finance opportunities. seeking be will indicated, to drive
please. go next slide, to the Let's
present second for tissue, clinical clinical interrogate to studies. studies clinical we validate have treatment. after we tissue opportunity a of cellular concept biopsy for extraordinarily as trials the of -- seek pretreatment samples tumor neoadjuvant is are that proof neoadjuvant an and molecule. and molecular tumor valuable us The tissue these program the to Getting to grouping both or on our tumor us in
the positive patients our combining We Cancer Portland, cancer inhibitor matropebamute meaning Oregon. interrogate. and has be in study, tumor all this tissue the are letrozole first of and -- Providence hormone will patients Center enrolled we we HERX-negative the have breast a resection have receptor in at beyond breast In the begin partners of them first pairs aromatase in first cohort half in to study to of the cancer fact, surgical with
We conferences, San and intrigetting to Breast. have upcoming we have both SITC abstracts and scientific begun Antonio submitted that,
but bladder this the interrogate to non-muscle with in tissue, in The in a also our setting is this the us second We're Shook MIBC. invasive doing neoadjuvant similar to in partners cancer way trial Quebec. the designed prenon-treatment is at allow
be year. this of have treated at to on first beginning the of to year's cohort That enrolled the cohort a The nevropepmuds. expect Preliminary is GU present able ASCO the patients with first we data study. next perhaps singularly
cancer inspire to cohort safety product, activity designed the second DPX second understand this an different reach begin antigens, DPX to It clinical This response platform. the MAGE-AX X to the the the only helps to allow but us simultaneously. the immune interrogate basis this clinical new and us for provide our of product Importantly, Serge. not product, helps study entire survivin will and for it understanding is of
very the next So activity forward verify much that dual few looking months. being in across we're able targeted clinic to the to
Let's that go The based to the review next is slide, to I'd like our platform. bit really please. upon last
platform, said, in adamantly we interested strategic we effective. engaging allow really be that a platform is Andrew truly time think are As to for the the and may cancer vaccines first multiple partners revolutionary around
existed. formulation, formulations cancer to that information vaccine deficiencies or efforts, as immune cases, In specific in peptides look single response. efficiencies the were recognize most I those system. package those a we that as specific those As think historical well could about a fact educate primarily, antigens have not the the we the can include at activators And
after the were technology interact is the injection cargo. this package of into single formulations system protecting even circulation those other that surrounding very the a antigens, limits information. response, package the those peptides, components antigens response, lipid messenger virus-like specific like are immune receptor like immune STING of recognition proteins ultimately different. to a incapable systemic formulation cargo immune-educating CPGs. immune single anticancer ability unique of with the chemistry, cargo, We educating and is oil IDC, the can that a of system including It innate whole addition, agonists formulation, appropriately an like a to with that This wide tissues pattern In activators for educators platform is RNAs, IMV. specific leach the and and Poly to in immune a immune of or DPX and whether variety particles, that perhaps unique very allowing the
cargo As packaging for remain protracted into an the that to cargo of injection of tissue. oil-based time. of the that allows at formulation, this leaching for site It DPX prevents period a
and consumed the immune system much can cargo educate a to take as used the lymph by it immune cells only that to actively response nodes As immune the consequence, relevant. traffic more doing. to of the an It's be immune that is very physiologically specific system
not and years. durable and responses of in and and in data in us now looking plug-and-play robust show that platform Merck that see be, multiple technology. both fail Brody stable specific from product, with lead in in those the well same bladder With Head to rest studies cancers. just responses are very DPX eliciting we've DPX us both KGaA. in our to ovarian cancers. as and depth we solid effective persist cascade MAVROopands. achieved potential out our X DLBCL beyond may is peptides In an multiple exemplar year. hematologic product we're that response a reported presentation the forward platform, show that reviewed see I very These at disease peptides the much clinical very the lead is We concert DPX in benefit that the were durable clinical those very appreciate turn clinical leveraging originally this potential immunity over cancers. advanced we to game-changing can as survivin for indications, far Finance, through what In that, survival the the with help we types, designed and so cancer and We those show Our cancers exactly that will They immune peptides specific benefit. Marcus by MABR complete of Davidson. originally long-term company formulations, of and in-licensing the developed was born conventional for partial and the the
